Inhibidor do activador do plasminóxeno 1 (Galician Wikipedia)

Analysis of information sources in references of the Wikipedia article "Inhibidor do activador do plasminóxeno 1" in Galician language version.

refsWebsite

Global rank Galician rank

4^th place

6^th place

2^nd place

7^th place

4,380^th place

1,519^th place

doi.org

Vaughan DE (August 2005). "PAI-1 and atherothrombosis". Journal of Thrombosis and Haemostasis 3 (8): 1879–83. PMID 16102055. doi:10.1111/j.1538-7836.2005.01420.x.
Carter JC, Church FC (2009). "Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1". PPAR Research 2009: 345320. PMC 2723729. PMID 19672469. doi:10.1155/2009/345320.
Elokdah H, Abou-Gharbia M, Hennan JK, McFarlane G, Mugford CP, Krishnamurthy G, Crandall DL (July 2004). "Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization". Journal of Medicinal Chemistry 47 (14): 3491–4. PMID 15214776. doi:10.1021/jm049766q.
Pautus S, Alami M, Adam F, Bernadat G, Lawrence DA, De Carvalho A, Ferry G, Rupin A, Hamze A, Champy P, Bonneau N, Gloanec P, Peglion JL, Brion JD, Bianchini EP, Borgel D (2016). "Characterization of the Annonaceous acetogenin, annonacinone, a natural product inhibitor of plasminogen activator inhibitor-1". Scientific Reports 6: 36462. PMC 5120274. PMID 27876785. doi:10.1038/srep36462.
Boncela J, Papiewska I, Fijalkowska I, Walkowiak B, Cierniewski CS (September 2001). "Acute phase protein alpha 1-acid glycoprotein interacts with plasminogen activator inhibitor type 1 and stabilizes its inhibitory activity". The Journal of Biological Chemistry 276 (38): 35305–11. PMID 11418606. doi:10.1074/jbc.M104028200.

Vaughan DE (August 2005). "PAI-1 and atherothrombosis". Journal of Thrombosis and Haemostasis 3 (8): 1879–83. PMID 16102055. doi:10.1111/j.1538-7836.2005.01420.x.
Carter JC, Church FC (2009). "Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1". PPAR Research 2009: 345320. PMC 2723729. PMID 19672469. doi:10.1155/2009/345320.
Elokdah H, Abou-Gharbia M, Hennan JK, McFarlane G, Mugford CP, Krishnamurthy G, Crandall DL (July 2004). "Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization". Journal of Medicinal Chemistry 47 (14): 3491–4. PMID 15214776. doi:10.1021/jm049766q.
Pautus S, Alami M, Adam F, Bernadat G, Lawrence DA, De Carvalho A, Ferry G, Rupin A, Hamze A, Champy P, Bonneau N, Gloanec P, Peglion JL, Brion JD, Bianchini EP, Borgel D (2016). "Characterization of the Annonaceous acetogenin, annonacinone, a natural product inhibitor of plasminogen activator inhibitor-1". Scientific Reports 6: 36462. PMC 5120274. PMID 27876785. doi:10.1038/srep36462.
Boncela J, Papiewska I, Fijalkowska I, Walkowiak B, Cierniewski CS (September 2001). "Acute phase protein alpha 1-acid glycoprotein interacts with plasminogen activator inhibitor type 1 and stabilizes its inhibitory activity". The Journal of Biological Chemistry 276 (38): 35305–11. PMID 11418606. doi:10.1074/jbc.M104028200.